Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | GAA | P10253 | 6/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | GLA | P06280 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442789 | 0.84 | KDM4E (0.59) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL3163773 | 0.83 | KDM4E (0.77) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL3169932 | 0.81 | KDM4E (0.73) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL14491422 | 0.81 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL5445204 | 0.80 | KDM4E (0.73) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL30263726 | 0.80 | TUBB4A (0.69) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL3170154 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL14491502 | 0.76 | KDM4E (0.71) | ALDH1A1KDM4EHPGDGAAL3MBTL1 | |
| SCHEMBL3090231 | 0.75 | JAK1 (1.00) | ALDH1A1KDM4EHPGDHTTJAK1 | |
| SCHEMBL3161525 | 0.75 | KDM4E (0.64) | ALDH1A1KDM4EHPGDGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1674454-A1 | SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ALDH1A1 208/4885KDM4E 2344/4885HPGD 2052/4885 |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | ADORA1, ADORA2B, ADORA3 | ALDH1A1 75/4885KDM4E 3781/4885HPGD 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.